Efficacy of ergometrine combined with carboprost tromethamine in the treatment of high-risk parturients for postpartum hemorrhage
NI Yinfang
CHEN Xunyan
LIU Xiaojing
Abstract：Objective To investigate the efficacy of carboprost tromethamine combined with ergometrine in the treatment of high-risk parturients for postpartum hemorrhage(PPH).Methods A total of 100 parturients with high-risk factors for PPH treated at Ningde Municipal Hospital of Ningde Normal University from May 2022 to May 2025 was retrospectively selected and divided into the carboprost group and the ergometrine group based on the medication regimen,with 50 cases in each group.The carboprost group was treated with carboprost tromethamine,while the ergometrine group was treated with car-boprost tromethamine combined with ergometrine.The clinical efficacy,bleeding conditions(total bleeding loss at 2 hours and 24 hours postpartum),postpartum recovery(duration of uterine contractions,duration of red and serous lochia,and hemostasis time),coagulation function indicators(activated partial thromboplastin time(APTT),prothrombin time(PT),fibrinogen(FIB)),blood routine indicators(hemoglobin(Hb),platelet count(PLT)),and adverse reactions between the two groups were compared.Results The total effective rate in the ergometrine group was 94.00%(47/50),higher than that in the carboprost group(74.00%,37/50)(χ2=7.440,P＜0.05).The total blood loss at 2 h and 24 h postpartum in the ergometrine group((436.20±70.61)mL,(489.90±64.78)mL,respectively)were less than those in the carboprost group((478.60±73.22)mL,(549.06±65.82)mL,respectively)(t=2.947,4.529,both P＜0.05).The duration of uterine contraction in the ergometrine group((3.78±1.86)h)was longer than that in the carboprost group((1.85±0.91)h)(t=6.591,P＜0.05).The duration of red and serous lochia and hemostasis time in the ergometrine group((14.24±2.08)d,(10.18±1.82)h,respectively)were shorter than those in the carboprost group((20.56±2.25)d,(17.24±1.29)h,respectively)(t=14.690,22.381,both P＜0.05).The levels of PT,APTT,and FIB in both groups decreased compared to pre-treatment levels,and the above indicators in the ergometrine group((9.68±0.53)s,(29.99±1.36)s,(2.96±0.30)g/L)were lower than those in the carboprost group((10.53±0.66)s,(32.85±1.76)s,(3.31±0.27)g/L)(t=7.101,9.092,6.132,all P＜0.05).Both groups showed decreased levels of Hb and PLT compared to pre-treatment values,and the levels of Hb and PLT in the ergometrine group((115.06±15.63)g/L,(191.04±24.70)×109/L)were higher than those in the carboprost group((108.14±12.29)g/L,(180.80±25.97)×109/L)(t=2.461,2.176,both P＜0.05).The incidence of adverse reactions was 10.00%(5/50)in the ergometrine group and 18.00%(9/50)in the carboprost group,with no statistically obvious difference between the two groups(χ2=1.329,P＞0.05).Conclusion The combination of carboprost tromethamine and ergometrine demonstrates good efficacy in treating high-risk parturients for PPH.It can effectively improve postpartum recovery,promote the recovery of coag-ulation function,control blood loss,shorten hemostasis time,with a favorable safety profile.
Keywords：carboprost tromethamineergometrinepostpartum hemorrhagehigh-risk factorefficacy
Publication Date：2025-12-25
Online Publishing Date：2026-01-07(First online date of this platform, not the publication date of the document)
Pages：5( 1560-1564 )